Literature DB >> 24225484

Clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute.

Erhan Turkoglu1, Bora Gurer, Ahmet M Sanli, Habibullah Dolgun, Levent Gurses, Nezih A Oral, Teoman Donmez, Zeki Sekerci.   

Abstract

OBJECTIVE: Low grade gliomas (LGGs) are slow-growing primary brain tumors with heterogeneous clinical behaviors. The aim of our study is to review the treatment outcome of 63 patients with LGGs focusing on surgical outcome and the current therapeutic strategy.
METHODS: We retrospectively enrolled 63 patients surgically treated for LGGs. The gross total resection (GTR) was performed in 35 patients (60.3%), subtotal resection (STR) was performed in 19 patients (31.7%) and partial resection (PR) or biopsy was performed in 9 patients (14.3%). We analyzed their progression-free survival (PFS), overall survival (OS), and malignant transformation with regard to age, gender, Karnofsky performance score (KPS), clinical presentation, tumor location, radiologic pattern, contrast enhancement, extent of removal, pathologic subtype, chemotherapy (CT) and radiotherapy (RT) treatment.
RESULTS: Among all LGGs, the 3-year OS rate was 80% and the 5-year OS was 76%. The 3-year PFS rate was 83.6% and the 5-year PFS was 25%. The non-eloquent area location showed a longer PFS than the eloquent area location (p=0.05). Oligodendroglial pathology showed a longer PFS compared to oligoastrocytomas and astrocytomas (p=0.02). Patients older than 60 years had poorer OS than younger patients (p<0.05). Female gender had a shorter OS than male gender (p<0.05), and a KPS of 90 or 100 had a longer OS than a KPS of 80 (p<0.05). Oligodendroglial pathology statistically correlated with a longer OS (p<0.05).
CONCLUSION: The findings from our study, which were confirmed by uni- and multivariate analyses, demonstrated that radical tumor resection was associated with better long-term outcomes and tumor progression for patients with LGG.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Extent of resection; Low grade glioma; Malignant transformation; Prognostic factors; Survival

Mesh:

Year:  2013        PMID: 24225484     DOI: 10.1016/j.clineuro.2013.10.010

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Prognosis of older patients with low-grade glioma: A retrospective study.

Authors:  Priya Kumthekar; Vaibhav Patel; Carly Bridge; Alfred Rademaker; Irene Helenowski; Maciej M Mrugala; Jason K Rockhill; Sean Grimm; Kristin R Swanson; Jeffrey Raizer
Journal:  Integr Cancer Sci Ther       Date:  2017-10-23

2.  Whole Chromosome 7 Gain Predicts Higher Risk of Recurrence in Pediatric Pilocytic Astrocytomas Independently From KIAA1549-BRAF Fusion Status.

Authors:  Jacquelyn J Roth; Tamara M Fierst; Angela J Waanders; Li Yimei; Jaclyn A Biegel; Mariarita Santi
Journal:  J Neuropathol Exp Neurol       Date:  2016-03-04       Impact factor: 3.685

3.  Awake Craniotomy with Noninvasive Brain Mapping by 3-Tesla Functional Magnetic Resonance Imaging for Excision of Low-grade Glioma: A Case of a Young Patient from Pakistan.

Authors:  Atta Ul Aleem Bhatti; Nasir Khan Jakhrani; Maria Adnan Parekh
Journal:  Asian J Neurosurg       Date:  2018 Apr-Jun

4.  Malignant Progression of Diffuse Low-grade Gliomas: A Systematic Review and Meta-analysis on Incidence and Related Factors.

Authors:  Satoshi Nakasu; Yoko Nakasu
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-02-22       Impact factor: 2.036

5.  Genome-wide analyses of the prognosis-related mRNA alternative splicing landscape and novel splicing factors based on large-scale low grade glioma cohort.

Authors:  Wang-Rui Liu; Chuan-Yu Li; Wen-Hao Xu; Xiao-Juan Liu; Hai-Dan Tang; Hai-Neng Huang
Journal:  Aging (Albany NY)       Date:  2020-07-13       Impact factor: 5.682

6.  Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit.

Authors:  Tiphaine Obara; Marie Blonski; Cyril Brzenczek; Sophie Mézières; Yann Gaudeau; Celso Pouget; Guillaume Gauchotte; Antoine Verger; Guillaume Vogin; Jean-Marie Moureaux; Hugues Duffau; Fabien Rech; Luc Taillandier
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.